Eversept Partners’s Cidara Therapeutics CDTX Stock Holding History

Eversept Partners’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-98,721	Closed	-$21.8M	–	126
2025 Q4	$21.8M	Buy	+98,721	New	+$16M	1.1%	23
2018 Q1	–	Sell	-2,500	Closed	-$340K	–	59
2017 Q4	$340K	Buy	+2,500	New	+$379K	0.2%	41

Eversept Partners's CDTX Position: Q1 2026 in Review

Eversept Partners sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 98,721 shares — an estimated $21.8M sold.

Eversept Partners first reported a position in CDTX in Q4 2017 and held it in 2 quarters. The position peaked at $21.8M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Eversept Partners reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Eversept Partners sold 98,721 Cidara Therapeutics shares in Q1 2026, an estimated $21.8M.
Eversept Partners first reported a position in Cidara Therapeutics in Q4 2017 and held it in 2 quarters.
Eversept Partners's Cidara Therapeutics position peaked at $21.8M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.